ACOG Share Price Performance
US$0
-8.09 (-100.00%)
Price US$0
Fair ValueUS$16.75
Share Pricen/a
Narrative Update • Aug 16
Alpha Cognition Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
ACOG Community Narratives
AN
Fair Value
·Fair Value US$16.75 46.9% undervalued intrinsic discount
Long-Term Care Adoption And International Expansion Will Drive Durable Cognitive Therapy Demand
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$12 25.9% undervalued intrinsic discount
Payer Friction And Slow Adoption Will Challenge Alzheimer’s Therapy Before Long Term Potential Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$18 50.6% undervalued intrinsic discount
Long Term Care Adoption And Real World Studies Will Transform This Cognitive Therapy Narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Long-Term Care Adoption And International Expansion Will Drive Durable Cognitive Therapy Demand
A little-known Alzheimer’s treatment is gaining traction in long-term care homes, helped by improving insurance coverage and fresh real-world studies that could make doctors more confident using it. The big question is whether wider access and overseas partnerships arrive fast enough to outpace rising costs, safety worries, and tougher pricing pressure from insurers.Read more
AN
US$16.75
46.9% undervalued intrinsic discount
Fair Value
Profit Margin
15.77%
Future PE
28.28x
Price in 2029
US$11.27
Payer Friction And Slow Adoption Will Challenge Alzheimer’s Therapy Before Long Term Potential Emerges
Alpha Cognition’s Alzheimer’s drug targets long-term care patients, but getting insurers and facilities to pay for and adopt it may take longer than many expect. The story hinges on whether real-world study results and easier-to-use versions can break through slow prescribing habits before cash burn and dilution become the bigger issue.Read more
AN
US$12
25.9% undervalued intrinsic discount
Fair Value
Profit Margin
19.7%
Future PE
21.9x
Price in 2029
US$8.03
Long Term Care Adoption And Real World Studies Will Transform This Cognitive Therapy Narrative
Catalysts About Alpha Cognition Alpha Cognition develops and commercializes therapies for cognitive disorders, with a primary focus on Alzheimer’s disease through its oral treatment ZUNVEYL. What are the underlying business or industry changes driving this perspective?Read more
AN
US$18
50.6% undervalued intrinsic discount
Fair Value
Profit Margin
14.36%
Future PE
25.95x
Price in 2029
US$12.28
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ACOG: Phase 4 Tolerability And Payer Progress Will Support Future Launch
Fair Value: US$16.75 46.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ACOG: Early Dementia Therapy Launch Will Drive Bullish Repricing Potential
Fair Value: US$12 25.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Term Care Adoption And Real World Studies Will Transform This Cognitive Therapy Narrative
Fair Value: US$18 50.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alpha Cognition Inc. Key Details
About ACOG
- Founded
- 2000
- Employees
- 71
- CEO
- WebsiteView website
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
